IFNA1 and asthma: The increased production of IFN-α and IFN-λ in 9 out of 10 patients treated with omalizumab for 6 months was statistically significant against influenza virus A, it showed a positive trend versus HRV and it was accompanied by an improvement in control of asthma symptoms [57].